Tags

Type your tag names separated by a space and hit enter

Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years.
Clin Exp Allergy. 2012 Jan; 42(1):112-22.CE

Abstract

BACKGROUND

Allergic disease has been associated with altered intestinal microbiota. Therefore, probiotics have been suggested as a potential treatment for eczema.

OBJECTIVE

We investigated whether dietary supplementation of infants with eczema at age 3-6 months with Lactobacillus paracasei CNCM I-2116 or Bifidobacterium lactis CNCM I-3446 had a treatment effect or altered allergic disease progression.

METHODS

Primary outcome included eczema severity (SCORing Atopic Dermatitis, SCORAD) 3 months post-randomization. Secondary: SCORAD (other visits); infant dermatitis quality of life (IDQoL); gastrointestinal permeability; urinary eosinophilic protein X; allergen-sensitization; allergic symptoms (age 12, 18, 36 months). A total of 208 infants aged 3-6 months with physician-diagnosed eczema were recruited; 137/208 (SCORAD ≥ 10, consuming ≥ 200 mL standard formula/day) were randomized to daily supplements containing L. paracasei or B. lactis or placebo for a 3-month period, while receiving extensively hydrolysed whey-formula (dairy-free diet). There were two open observational groups, one group exclusively breastfed (n = 22) and the other, standard formula-fed (n = 49).

TRIAL NUMBER

ISRCTN41490500.

RESULTS

Eczema severity decreased significantly over time in all groups. No significant difference was observed between randomized groups after 12-week treatment-period (SCORAD-score pre-/post-intervention: B. lactis 25.9 [95% CI: 22.8-29.2] to 12.8 [9.4-16.6]; L. paracasei 25.4 [22.1-29] to 12.5 [9.2-16.4]; placebo 26.9 [23.4-30.6] to 11.8 [9.6-14.3]; P = 0.7). Results were similar when analysis was controlled for allergen-sensitization, or when only sensitized infants were analysed. No differences were found for secondary outcomes. No difference was observed in SCORAD-score between randomized and observational groups.

CONCLUSION AND CLINICAL RELEVANCE

We found no benefit from supplementation with B. lactis or L. paracasei in the treatment of eczema, when given as an adjunct to basic topical treatment, and no effect on the progression of allergic disease from age 1 to 3 years.

Authors+Show Affiliations

School of Translational Medicine, University of Manchester, NIHR Translational Research Facility in Respiratory Medicine, University Hospital of South Manchester NHS Foundation Trust, Manchester, UK. cgore@nhs.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22092692

Citation

Gore, C, et al. "Treatment and Secondary Prevention Effects of the Probiotics Lactobacillus Paracasei or Bifidobacterium Lactis On Early Infant Eczema: Randomized Controlled Trial With Follow-up Until Age 3 Years." Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, vol. 42, no. 1, 2012, pp. 112-22.
Gore C, Custovic A, Tannock GW, et al. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy. 2012;42(1):112-22.
Gore, C., Custovic, A., Tannock, G. W., Munro, K., Kerry, G., Johnson, K., Peterson, C., Morris, J., Chaloner, C., Murray, C. S., & Woodcock, A. (2012). Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 42(1), 112-22. https://doi.org/10.1111/j.1365-2222.2011.03885.x
Gore C, et al. Treatment and Secondary Prevention Effects of the Probiotics Lactobacillus Paracasei or Bifidobacterium Lactis On Early Infant Eczema: Randomized Controlled Trial With Follow-up Until Age 3 Years. Clin Exp Allergy. 2012;42(1):112-22. PubMed PMID: 22092692.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. AU - Gore,C, AU - Custovic,A, AU - Tannock,G W, AU - Munro,K, AU - Kerry,G, AU - Johnson,K, AU - Peterson,C, AU - Morris,J, AU - Chaloner,C, AU - Murray,C S, AU - Woodcock,A, Y1 - 2011/10/18/ PY - 2011/06/20/received PY - 2011/07/25/revised PY - 2011/08/12/accepted PY - 2011/11/19/entrez PY - 2011/11/19/pubmed PY - 2012/7/11/medline SP - 112 EP - 22 JF - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology JO - Clin. Exp. Allergy VL - 42 IS - 1 N2 - BACKGROUND: Allergic disease has been associated with altered intestinal microbiota. Therefore, probiotics have been suggested as a potential treatment for eczema. OBJECTIVE: We investigated whether dietary supplementation of infants with eczema at age 3-6 months with Lactobacillus paracasei CNCM I-2116 or Bifidobacterium lactis CNCM I-3446 had a treatment effect or altered allergic disease progression. METHODS: Primary outcome included eczema severity (SCORing Atopic Dermatitis, SCORAD) 3 months post-randomization. Secondary: SCORAD (other visits); infant dermatitis quality of life (IDQoL); gastrointestinal permeability; urinary eosinophilic protein X; allergen-sensitization; allergic symptoms (age 12, 18, 36 months). A total of 208 infants aged 3-6 months with physician-diagnosed eczema were recruited; 137/208 (SCORAD ≥ 10, consuming ≥ 200 mL standard formula/day) were randomized to daily supplements containing L. paracasei or B. lactis or placebo for a 3-month period, while receiving extensively hydrolysed whey-formula (dairy-free diet). There were two open observational groups, one group exclusively breastfed (n = 22) and the other, standard formula-fed (n = 49). TRIAL NUMBER: ISRCTN41490500. RESULTS: Eczema severity decreased significantly over time in all groups. No significant difference was observed between randomized groups after 12-week treatment-period (SCORAD-score pre-/post-intervention: B. lactis 25.9 [95% CI: 22.8-29.2] to 12.8 [9.4-16.6]; L. paracasei 25.4 [22.1-29] to 12.5 [9.2-16.4]; placebo 26.9 [23.4-30.6] to 11.8 [9.6-14.3]; P = 0.7). Results were similar when analysis was controlled for allergen-sensitization, or when only sensitized infants were analysed. No differences were found for secondary outcomes. No difference was observed in SCORAD-score between randomized and observational groups. CONCLUSION AND CLINICAL RELEVANCE: We found no benefit from supplementation with B. lactis or L. paracasei in the treatment of eczema, when given as an adjunct to basic topical treatment, and no effect on the progression of allergic disease from age 1 to 3 years. SN - 1365-2222 UR - https://www.unboundmedicine.com/medline/citation/22092692/Treatment_and_secondary_prevention_effects_of_the_probiotics_Lactobacillus_paracasei_or_Bifidobacterium_lactis_on_early_infant_eczema:_randomized_controlled_trial_with_follow_up_until_age_3_years_ L2 - https://doi.org/10.1111/j.1365-2222.2011.03885.x DB - PRIME DP - Unbound Medicine ER -